TIC10 compound

01/01/2019 - "To investigate the mechanism of ONC201 and identify compounds with improved potency, we tested a series of novel ONC201 analogues (TR compounds) for effects on cell viability and stress responses in breast and other cancer models. "
07/11/2023 - "We evaluated the efficacy of L_GEM and ONC201 in PanCan cells, and "KrasLSL-G12D; p53LoxP; Pdx1-CreER (KPC) triple mutant xenograft tumor-bearing mice. "
10/03/2023 - "Results from the phase I/II trials of ONC201 in patients with refractory solid tumors demonstrated tumor responses and prolonged stable disease in some patients. "
01/01/2022 - "Clinical trials showed that ONC201, the first in class imipridone, was well tolerated and exhibited tumor regression in some solid tumors. "
12/02/2021 - "ONC201 is the founding member of the imipridone class, comprised of orally bioavailable small molecules that have shown efficacy in multiple tumor types both in animal models and in Phase I/II clinical trials. "

01/01/2018 - "We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. "
01/01/2018 - "Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies."
02/16/2016 - "Thus, our results suggest that by inducing an atypical ISR and p53-independent apoptosis, ONC201 has clinical potential in hematological malignancies. "
02/16/2016 - "ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies."
01/01/2018 - "Imipridone ONC201: combination therapy in hematologic malignancies."

12/02/2021 - "Taken together, the preclinical efficacy of ONC201 and TLY012 represents a novel therapeutic option for further testing in pancreatic cancer patients. "
12/02/2021 - "We screened 7 pancreatic cancer cell lines and found synergy with ONC201 and rhTRAIL or the novel TRAIL receptor agonist TLY012 in 6 of the 7 cell lines tested. "
12/02/2021 - "We hypothesized that TRAIL receptor agonists might induce selective, synergistic apoptosis in pancreatic cancer cell lines treated with ONC201. "
01/01/2016 - "The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent."
12/02/2021 - "This combination showed marked efficacy in tumor cells that are both sensitive and resistant to the pro-apoptotic effects of ONC201, providing rationale to further investigate the combination of ONC201 plus TLY012 in patients with pancreatic cancer."

01/01/2022 - "We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). "
11/01/2020 - "ONC201 (TIC10) is currently used in phase 2 clinical trials to treat high-grade gliomas. "
01/01/2018 - "Recent phase I and II clinical trials have shown that ONC201 is well tolerated and may have single agent activity in high grade glioma patients among others. "
11/01/2023 - "Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways."
07/01/2023 - "Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas."

10/01/2017 - "ONC201: a new treatment option being tested clinically for recurrent glioblastoma."
01/01/2021 - "Immunohistochemical studies were performed on clinically annotated glioblastoma samples derived from patients treated with ONC201. "
10/03/2017 - "A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma."
01/01/2021 - "Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma."
01/01/2021 - "Treatment of macrophages-glioblastoma cells co-cultures with ONC201 induced similar alterations in glutamatergic and inflammatory gene expression profiles of macrophages. "